Drugs / Δ9-tetrahydrocannabinol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03782402 | Sep 2019 → Aug 2021 | chemotherapy-induced neuropathy | New York State Psychiatric Institute | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Δ9-tetrahydrocannabinol | “co-administration of two constituents of cannabis, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD)” PMID 40611810 ↗ Jul 2025 |
| Known as | THC | “co-administration of two constituents of cannabis, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD)” PMID 40611810 ↗ Jul 2025 |
| Route | Oral | “The goal of this 8-week, double-blind, randomized pilot study, conducted from 2019 to 2021, was to test the feasibility and tolerability of oral cannabis (100 mg CBD: 5 mg THC,...” PMID 40611810 ↗ Jul 2025 |